Featured Research

from universities, journals, and other organizations

Destined for disease: Breast cancer mutation regulates cell fate

Date:
February 4, 2011
Source:
Cell Press
Summary:
Breast tissue cells from certain individuals make abnormal cell-fate decisions even before cancer develops. This provides exciting new insights into the mechanisms behind one of the most lethal types of breast cancer.

A new study sheds light on why individuals who inherit a particular family of mutations have a high risk of developing a very aggressive form of breast cancer. The research, published by Cell Press on February 4th in the journal Cell Stem Cell, shows that breast tissue cells from these individuals make abnormal cell-fate decisions even before cancer develops and provides exciting new insights into the mechanisms behind one of the most lethal types of breast cancer.

There are many forms of human breast cancer. Mutations in the BRCA1 tumor suppressor gene are associated with the development of the "basal-like" subtype of breast cancer which exhibits a very poor prognosis. "Recent evidence has indicated that BRCA1 might regulate breast cell differentiation," explains senior study author Dr. Charlotte Kuperwasser, Associate Professor in anatomy and cellular biology from Tufts University School of Medicine and member of the Sackler School of Graduate Biomedical Sciences at Tufts. "We wanted to examine whether BRCA1's role in differentiation was associated with the increased development of basal-like breast cancer."

Dr. Kuperwasser's group examined disease-free breast tissues from patients with normal or mutant BRCA1 genes. Using an ingenious strategy that allowed them to mimic the environment of intact human breast tissue, they transplanted the human cells into mice and looked at the types of tumors that formed after the cells were exposed to additional cancer-promoting signals. Although the cells with normal BRCA1 grew into different kinds of breast cancer, the cells from women with BRCA1 mutations mostly formed the aggressive basal-like tumors. Importantly, molecular analysis of disease-free breast cells with mutated BRCA1 revealed that even before tumors developed, the mutant cells were more likely to remain immature and contain elevated levels of a protein called Slug. The researchers showed that when Slug is present in the breast, cells are unable to undergo proper maturation and are stalled in a premature state of development. This premature state of development is subsequently retained in basal-like breast cancers.

These findings show that BRCA1 mutations significantly impact breast cell maturation even before the patients manifest an increased risk for breast cancer. In a sense, the BRCA1 mutation "stacks the deck" towards a basal-like tumor phenotype by biasing differentiation towards this state. "Future studies will be necessary to fully dissect the precise domains and mechanisms by which BRCA1 regulates breast epithelial differentiation," concludes Dr. Kuperwasser. "In addition, further experiments will be needed to determine whether certain mutations in BRCA1 affect differentiation and regulate cell fate differently and whether different mutations alter the propensity for the development of basal-like tumors."


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Journal Reference:

  1. Theresa A. Proia, Patricia J. Keller, Piyush B. Gupta, Ina Klebba, Ainsley D. Jones, Maja Sedic, Hannah Gilmore, Nadine Tung, Stephen P. Naber, Stuart Schnitt et al. Genetic Predisposition Directs Breast Cancer Phenotype by Dictating Progenitor Cell Fate. Cell Stem Cell, Volume 8, Issue 2, 149-163, 4 February 2011 DOI: 10.1016/j.stem.2010.12.007

Cite This Page:

Cell Press. "Destined for disease: Breast cancer mutation regulates cell fate." ScienceDaily. ScienceDaily, 4 February 2011. <www.sciencedaily.com/releases/2011/02/110203124720.htm>.
Cell Press. (2011, February 4). Destined for disease: Breast cancer mutation regulates cell fate. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/02/110203124720.htm
Cell Press. "Destined for disease: Breast cancer mutation regulates cell fate." ScienceDaily. www.sciencedaily.com/releases/2011/02/110203124720.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins